Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity

The FDA has granted fast track designation to Quince Therapeutics’ Phase III drug candidate EryDex to treat rare disease ataxia-telangiectasia. Credit: grandbrothers via Shutterstock. California-based

Eli Lil­ly is ex­pand­ing its pri­vate fi­nanc­ing am­bi­tions, part­ner­ing with ven­ture cap­i­tal firm An­dreessen Horowitz on a new $500 mil­lion biotech fund. The phar­ma com­pa­ny